Development of Therapeutic Options on Type 2 Diabetes in Years: Glucagon-like Peptide-1 Receptor Agonist's Role Intreatment; from the Past to Future

Overview

Journal World J Diabetes

Publisher Baishideng Publishing Group

Specialty Endocrinology

Date 2019 Sep 17

PMID 31523380

Citations 12

Authors

Hakan Dogruel

Mustafa Kemal Balci

Affiliations

Soon will be listed here.

Abstract

Diabetes mellitus (DM) is a chronic metabolic disease characterized by hypergly-cemia. Type 2 diabetes (T2DM) accounting for 90% of cases globally. The worldwide prevalence of DM is rising dramatically over the last decades, from 30 million cases in 1985 to 382 million cases in 2013. It's estimated that 451 million people had diabetes in 2017. As the pathophysiology was understood over the years, treatment options for diabetes increased. Incretin-based therapy is one of them. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) not only significantly lower glucose level with minimal risk of hypoglycemia but also, they have an important advantage in themanagement of cardiovascular risk and obesity. Thus, we will review here GLP-1 RAsrole in the treatment of diabetes.

Citing Articles

Hyaluronic Acid Treatment of Post-Extraction Tooth Socket Healing in Subjects with Diabetes Mellitus Type 2: A Randomized Split-Mouth Controlled Study.

Ruggiero T, Carossa M, Camisassa D, Bezzi M, Rivetti G, Nobile V J Clin Med. 2024; 13(2).

PMID: 38256586 PMC: 10816872. DOI: 10.3390/jcm13020452.

Research Progress on Absorption, Metabolism, and Biological Activities of Anthocyanins in Berries: A Review.

Xue H, Sang Y, Gao Y, Zeng Y, Liao J, Tan J Antioxidants (Basel). 2023; 12(1).

PMID: 36670865 PMC: 9855064. DOI: 10.3390/antiox12010003.

Identification of sitagliptin binding proteins by affinity purification mass spectrometry.

Wang X, Sim B, Chen H, Zheng Y, Xue J, Wang L Acta Biochim Biophys Sin (Shanghai). 2022; 54(10):1453-1463.

PMID: 36239351 PMC: 9827809. DOI: 10.3724/abbs.2022142.

Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction.

Yang S, Li Y, Liu C, Wu Y, Wan Z, Shen D Front Endocrinol (Lausanne). 2022; 13:949535.

PMID: 36213270 PMC: 9538860. DOI: 10.3389/fendo.2022.949535.

Role of mitochondrial DNA in diabetes Mellitus Type I and Type II.

Al-Ghamdi B, Al-Shamrani J, El-Shehawi A, Al-Johani I, Al-Otaibi B Saudi J Biol Sci. 2022; 29(12):103434.

PMID: 36187456 PMC: 9523097. DOI: 10.1016/j.sjbs.2022.103434.

References

Butler A, Janson J, Bonner-Weir S, Ritzel R, Rizza R, Butler P . Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2002; 52(1):102-10. DOI: 10.2337/diabetes.52.1.102. View

Kjems L, Holst J, Volund A, Madsbad S . The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003; 52(2):380-6. DOI: 10.2337/diabetes.52.2.380. View

Mortensen K, Christensen L, Holst J, Orskov C . GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept. 2003; 114(2-3):189-96. DOI: 10.1016/s0167-0115(03)00125-3. View

Eissele R, Goke R, Willemer S, Harthus H, Vermeer H, Arnold R . Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest. 1992; 22(4):283-91. DOI: 10.1111/j.1365-2362.1992.tb01464.x. View

Knop F, Vilsboll T, Hojberg P, Larsen S, Madsbad S, Volund A . Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. Diabetes. 2007; 56(8):1951-9. DOI: 10.2337/db07-0100. View

Nissen S, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24):2457-71. DOI: 10.1056/NEJMoa072761. View

Lee Y, Kwon M, Kang E, Park Y, Choi S, Ahn C . Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. J Gene Med. 2007; 10(3):260-8. DOI: 10.1002/jgm.1153. View

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

10.

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

11.

Kim W, Egan J . The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008; 60(4):470-512. PMC: 2696340. DOI: 10.1124/pr.108.000604. View

12.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven P . Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2008; 360(2):129-39. DOI: 10.1056/NEJMoa0808431. View

13.

DeFronzo R . Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4):773-95. PMC: 2661582. DOI: 10.2337/db09-9028. View

14.

Bonds D, Miller M, Bergenstal R, Buse J, Byington R, Cutler J . The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340:b4909. PMC: 2803744. DOI: 10.1136/bmj.b4909. View

15.

Meier J, Nauck M . Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?. Diabetes. 2010; 59(5):1117-25. PMC: 2857890. DOI: 10.2337/db09-1899. View

16.

Best J, Hoogwerf B, Herman W, Pelletier E, Smith D, Wenten M . Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2010; 34(1):90-5. PMC: 3005487. DOI: 10.2337/dc10-1393. View

17.

Ahren B, Carr R, Deacon C . Incretin hormone secretion over the day. Vitam Horm. 2010; 84:203-20. DOI: 10.1016/B978-0-12-381517-0.00007-2. View

18.

Bagger J, Knop F, Lund A, Vestergaard H, Holst J, Vilsboll T . Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96(3):737-45. DOI: 10.1210/jc.2010-2435. View

19.

Mentis N, Vardarli I, Kothe L, Holst J, Deacon C, Theodorakis M . GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes. 2011; 60(4):1270-6. PMC: 3064100. DOI: 10.2337/db10-1332. View

20.

Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D . GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin. 2011; 27(8):1519-28. DOI: 10.1185/03007995.2011.590127. View